XML 204 R20.htm IDEA: XBRL DOCUMENT
v3.26.1

Lease | 12 Months Ended
--- | ---
Dec. 31, 2025 | May 31, 2025
Lease [Line Items] |  |
LEASE | 14. LEASE As of December 31, 2025, the Group has a long-term operating lease for laboratories with remaining term expiring in 2026 and a remaining lease term of 0.2 years. Weighted average discount rates used in the calculation of the operating lease liability is 8%. The discount rates reflect the estimated incremental borrowing rate, which includes an assessment of the credit rating to determine the rate that the Group would have to pay to borrow, on a collateralized basis for a similar term, an amount equal to the lease payments in a similar economic environment.
|  | For the year ended December 31, 2025 |  | For the year ended December 31, 2024 |  | For the year ended December 31, 2023
Lease cost |  |  |  |  |  |  |  |  |  |  |
Operating lease cost |  |  | — |  |  |  | 50,520 |  |  | 252,345 |
Short-term lease cost |  |  | — |  |  |  | 3,374 |  |  | 65,221 |
Total lease cost |  | $ | — |  |  | $ | 53,894 |  |  | 317,566 |
Other information |  |  |  |  |  |  |  |  |  |  |
Cash paid for amounts included in the measurement of lease liabilities |  |  |  |  |  |  |  |  |  |  |
Operating cash flows from operating leases |  | $ | 98,448 |  |  | $ | 120,824 |  |  | 389,365 |
Weighted-average remaining lease term – operating leases |  |  | 0.2 years |  |  |  | 1.2 years |  |  | 1.9 years |
Weighted-average discount rate – finance leases |  |  | — | % |  |  | — | % |  | — | %
Weighted-average discount rate – operating leases |  |  | 8.0 | % |  |  | 8.0 | % |  | 8.0 | %
For the years ended December 31, 2025, the Group did not recognize any impairment losses and loss on disposal of right-of-use assets. For the year ended December 31, 2024, an impairment loss of $144,051 on right-of-use assets was recognized in other operating expenses as the Group considered that the carrying amount of a right-of-use asset related to a lease of laboratory may not be recoverable. For the year ended December 31, 2023, an impairment loss of $200,916 on right-of-use assets was recognized in other operating expenses as the Group considered that the carrying amount of a right-of-use asset related to a lease of clinic may not be recoverable. Additionally, the Group early terminated a lease agreement for a right-of-use asset relating to an office, which resulted in a recognized loss on early termination of the right-of-use asset totaling $31,030 in other operating expenses. The maturity analysis of operating leases liabilities as of December 31, 2025 is as follows:
|  | December 31, 2025
Remaining periods ending December 31, |  |  |
2026 |  | 24,573 |
Total future undiscounted cash flow |  | 24,573 |
Less: Discount on operating lease liabilities |  | (145 | )
Present value of operating lease liabilities |  | 24,428 |
DiamiR Biosciences Corp. [Member] |  |
Lease [Line Items] |  |
LEASE |  | NOTE 9 — LEASES As of May 31, 2023, the Company had a lease for laboratory space with a term of one year and a one-year Company renewal option. The Company renewed the lease on a one-year basis in each of the years ended May 31, 2024 and 2025. The Company considers exercise of its renewal options to be probable. Accordingly, it has recorded right of use assets and lease liabilities related to the lease. The lease agreement does not provide an implicit borrowing rate; therefore, an internal incremental borrowing rate is determined based on information available at lease commencement date for purposes of determining the present value of lease payments and recording lease liabilities. In determining this rate, the Company estimated the rate of interest it would pay on collateralized loans with similar payment terms, in a similar economic environment, by reference to comparable lessee companies. Supplemental cash flow information and non-cash activity related to leases include the following in the years ended May 31:
|  | 2025 |  | 2024
Cash paid on operating lease liabilities |  | $ | 42,052 |  | $ | 40,827
Right of use assets acquired under operating leases |  | $ | 39,083 |  | $ | 37,319
Lease terms and assumed discount rates are as follows:
|  | May 31, 2025 |  | May 31, 2024
Average lease term |  | 1.6 years |  |  | 1.6 years |
Discount rate |  | 10 | % |  | 10 | %
Minimum lease payments under leases with terms greater than one year are as follows:
Year |  | Amount
Year ending May 31, 2026 |  | $ | 43,313 |
Year ending May 31, 2027 |  |  | 25,703 |
Total |  |  | 69,016 |
Less imputed interest |  |  | (4,935 | )
Lease liability |  | $ | 64,081 |
The Company also leases office space on a monthly basis. Total lease costs were $40,103 and $47,493 in the years ended May 31, 2025 and 2024, respectively

X
- References No definition available. + Details
Name: | apm_LeaseLineItems
Namespace Prefix: | apm_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details
Name: | us-gaap_LesseeOperatingLeasesTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_ConsolidatedEntitiesAxis=apm_DiamiRBiosciencesCorpMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |